Agilon Health (NYSE:AGL) Given New $170.00 Price Target at Wells Fargo & Company

Agilon Health (NYSE:AGL) had its target price upped by Wells Fargo & Company from $146.00 to $170.00 in a research report released on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

AGL has been the subject of a number of other reports. StoneX lifted their price target on Agilon Health from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Wednesday. Robert W. Baird set a $116.00 price objective on Agilon Health in a research note on Thursday, August 6th. Citigroup upgraded Agilon Health from a “sell” rating to a “neutral” rating and upped their price objective for the company from $105.00 to $115.00 in a research note on Monday, August 10th. Royal Bank Of Canada set a $125.00 target price on Agilon Health in a report on Tuesday, September 15th. Finally, Sanford C. Bernstein upgraded Agilon Health from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $86.00 to $125.00 in a research report on Tuesday, September 15th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Agilon Health has an average rating of “Hold” and a consensus target price of $107.38.

Agilon Health Stock Up 4.9%

AGL stock traded up $5.39 during mid-day trading on Friday, hitting $115.69. 152,510 shares of the company were exchanged, compared to its average volume of 219,597. The company has a market capitalization of $1.94 billion, a PE ratio of -20.84 and a beta of 3.10. The company has a current ratio of 1.13, a quick ratio of 1.13 and a debt-to-equity ratio of 0.06. Agilon Health has a twelve month low of $7.48 and a twelve month high of $133.04. The firm has a fifty day simple moving average of $90.70 and a 200 day simple moving average of $68.98.

Agilon Health (NYSE:AGL) last released its earnings results on Wednesday, November 4th. The company reported $1.97 earnings per share for the quarter, topping the consensus estimate of ($1.23) by $3.20. The company had revenue of $1.52 billion during the quarter, compared to the consensus estimate of $1.46 billion. Agilon Health had a negative net margin of 1.45% and a negative return on equity of 51.97%. On average, research analysts forecast that Agilon Health will post -2.90 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Sterling Capital Management LLC bought a new stake in shares of Agilon Health during the 3rd quarter valued at about $33,000. Root Financial Partners LLC acquired a new stake in Agilon Health during the third quarter worth about $57,000. State of Alaska Department of Revenue acquired a new stake in Agilon Health during the third quarter worth about $64,000. Allworth Financial LP acquired a new stake in Agilon Health during the second quarter worth about $114,000. Finally, Proficio Capital Partners LLC bought a new position in Agilon Health in the second quarter worth about $210,000.

About Agilon Health

Agilon Health is a U.S. healthcare company that partners with primary care physicians to provide care for patients enrolled in Medicare Advantage plans. Its model is designed to help physician groups move from traditional fee-for-service care toward value-based care, in which providers are rewarded for improving patients’ health and coordinating their care. The company provides participating physician groups with clinical, operational, technology and administrative support, along with resources to manage patient populations and coordinate care across local healthcare networks.